Dr Reddy's Q2 Profit Falls 36%, Brokerages Mixed on Outlook and Targets
Dr Reddy's Laboratories reported a 36% year-on-year profit decline to Rs 925 crore in Q2FY27, with a slight revenue drop due to lower North American sales. Despite this, sequential profit and revenue rose, supported by cost control and product launches like bosutinib. Brokerages offered mixed ratings: Nomura and Citi maintained positive outlooks with target price adjustments, Jefferies upgraded to 'Hold', while Goldman Sachs and Kotak Neo remained cautious. Key catalysts include the expected semaglutide relaunch and biosimilar abatacept approval in late 2026, with margin recovery anticipated over the next years.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (65/100). Lens Score 39/100.
Outlets measured: moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (62–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 26 Oct, 05:20 am. Other outlets followed.